Unknown

Dataset Information

0

Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity.


ABSTRACT: Exaggerated adrenergic activity is associated with human hypertension. The peptide urocortin 2 (Ucn 2) inhibits catecholamine synthesis and secretion from adrenal chromaffin cells in vitro and administration to mammals lowers blood pressure (BP). The chromogranin A-null mouse (Chga-/-) manifests systemic hypertension because of excessive catecholamine secretion from the adrenal and decreased catecholamine storage. In the present study, we investigated whether systemic administration of Ucn 2 could reduce BP and adrenal and plasma levels of catecholamines in vivo. Ucn 2 peptide was administered to freely moving, conscious Chga-/- and wild-type control mice. Telemetry and HPLC measured changes in BP and catecholamine levels, respectively. In both groups of mice, Ucn 2 dose-dependently decreased BP, and this effect was mediated by corticotropin factor-receptor type 2. However, in Chga-/- mice, the maximal percentage decrease of systolic BP from basal systolic BP was 37% compared with only a 23% reduction in wild-type mice (P=0.04). In Chga-/- mice only, Ucn 2 decreased adrenal and plasma levels of catecholamines as well as adrenal levels of tyrosine hydroxylase protein and phosphorylation. In vitro mechanistic studies demonstrated that Ucn 2 reduces both catecholamine secretion and tyrosine hydroxylase promoter activity, suggesting that the exaggerated action of Ucn 2 to reduce BP in the Chga-/- mouse is mediated through inhibition of both catecholamine synthesis and secretion. The data suggest that Ucn 2 may be therapeutically useful in regulating the exaggerated sympathoadrenal function of hyperadrenergic hypertension.

SUBMITTER: Gu Y 

PROVIDER: S-EPMC2946150 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity.

Gu Yusu Y   Zhang Kuixing K   Biswas Nilima N   Friese Ryan S RS   Lin Dennis H DH   Mahata Sushil K SK   Hoshijima Masahiko M   O'Connor Daniel T DT   Peterson Kirk L KL   Brar Bhawanjit K BK  

Endocrinology 20100728 10


Exaggerated adrenergic activity is associated with human hypertension. The peptide urocortin 2 (Ucn 2) inhibits catecholamine synthesis and secretion from adrenal chromaffin cells in vitro and administration to mammals lowers blood pressure (BP). The chromogranin A-null mouse (Chga-/-) manifests systemic hypertension because of excessive catecholamine secretion from the adrenal and decreased catecholamine storage. In the present study, we investigated whether systemic administration of Ucn 2 cou  ...[more]

Similar Datasets

| S-EPMC5425007 | biostudies-literature
| S-EPMC7754173 | biostudies-literature
| S-EPMC8528873 | biostudies-literature
| S-EPMC9194552 | biostudies-literature
| S-EPMC3986843 | biostudies-literature
2021-10-27 | GSE182566 | GEO
| S-EPMC6747395 | biostudies-literature
| S-EPMC4488299 | biostudies-literature
| S-EPMC7881801 | biostudies-literature
| S-EPMC4116673 | biostudies-literature